Patients with muscle-invasive bladder cancer who underwent whole pelvis radiation showed improved cancer-specific survival and overall survival.

cancer can spread into the muscle layers of the bladder wall. The main symptom for non–muscle invasive bladder cancer is hematuria, but once the cancer becomes muscle-invasive, it can cause some ...

Extended lymphadenectomy did not improve disease-free or overall survival compared to standard lymphadenectomy in muscle-invasive bladder cancer patients. Higher perioperative morbidity and mortality ...

Standard treatment for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by radical cystectomy, but more than half of all patients relapse within 3 years. Previous trials of ...

A recent study reveals that extended lymphadenectomy offers no survival advantage over standard lymphadenectomy for patients ...

Bladder cancer is the ninth most common cancer worldwide, and the number of diagnosed incident cases is set to increase.

This study included a review of consecutive patients diagnosed with NMIBC between January 2005 and May 2023 to identify ...

The FDA is currently evaluating the application of intravesical mitomycin for low-grade intermediate-risk non–muscle-invasive bladder cancer.

Bladder cancer is a highly recurrent disease with few treatment options available to patients,” said Ambaw Bellete, President & Chief Operating Officer, CG Oncology. “This program reflects our ...

for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The analyst writes, “Anktiva has the potential to revolutionize cancer ...

enGene’s lead program is detalimogene voraplasmid, (also known as detalimogene, and previously EG-70) for patients with ...